Consorcio Centro de Investigación Biomédica en Red, M.P. Report issue

Academic/Hospital Phase 3 Phase 4

Organization Overview

First Clinical Trial
2020
NCT04325061
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Consorcio Centro de Investigación Biomédica en Red (CIBER) | Consorcio Centro de Investigación Biomédica en Red, M.P.

Active Ingredients

Drugs in Phase 4 Trials (3)

aripiprazole (abilify) (1 trial)

dexamethasone (2 trials)

paliperidone (invega) (1 trial)

Drugs in Phase 3 Trials (2)

esmolol (brevibloc) (1 trial)

metoprolol (lopressor) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acute Lung Injury (Phase 4)

Infections (Phase 4)

Respiratory Distress Syndrome (Phase 4)

Respiratory Distress Syndrome, Newborn (Phase 4)

Respiratory Insufficiency (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 5
  • # of Trial APIs: 5